Rigel Pharmaceuticals Enters Collaboration And License Agreement With Grifols, S.A. To Commercialize Fostamatinib In Europe; Co. To Receive $30M Upfront Cash Payment With $297.5M In Potential Milestones
Benzinga Newsdesk